

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) Publication number:

0 196 132 B1

(12)

EUROPEAN PATENT SPECIFICATION

- (45) Date of publication of patent specification: **12.08.92** (51) Int. Cl.⁵: **C07D 413/14**, C07D 417/14,
C07D 513/04, C07D 487/04,
(21) Application number: **86200400.9** C07D 471/04, A61K 31/505,
//(C07D513/04,277:00,239:00),
(22) Date of filing: **13.03.86** (C07D513/04,279:00,239:00),
(C07D487/04,239:00,209:00),
(C07D487/04,239:00,223:00),
(C07D471/04,239:00,221:00)
- The file contains technical information submitted
after the application was filed and not included in
this specification

(54) **1,2-Benzisoxazol-3-yl and 1,2-benzisothiazol-3-yl derivatives.**

(30) Priority: **27.03.85 US 717067**

(43) Date of publication of application:
01.10.86 Bulletin 86/40

(45) Publication of the grant of the patent:
12.08.92 Bulletin 92/33

(84) Designated Contracting States:
AT BE CH DE FR GB IT LI LU NL SE

(56) References cited:
EP-A- 0 070 053 EP-A- 0 073 564
EP-A- 0 110 435 EP-A- 0 127 167
US-A- 4 342 870 US-A- 4 443 451

(73) Proprietor: **JANSSEN PHARMACEUTICA N.V.**
Turnhoutseweg 30
B-2340 Beerse(BE)

(72) Inventor: **Kennis, Ludo Edmond Josephine**
Guldo Gezellestraat 50
B-2300 Turnhout(BE)
Inventor: **Vandenberk, Jan**
Kempenlaan 15
B-2340 Beerse(BE)

BEST AVAILABLE COPY

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).


Description

In U.S. Patent No. 4,352,811 and U.S. Patent No. 4,458,076 there are described 3-piperidinyl-1,2-benzisoxazoles and 3-piperidinyl-1,2-benzisothiazoles having antipsychotic and analgesic properties.

EP-A-0 110 435 discloses ((bis(aryl)methylene)-1-piperidinyl)alkyl-pyrimidinones useful in the treatment of psychosomatic disorders. EP-A-0 070 053 discloses bicyclic pyrimidin-5-one derivatives being psychotropic agents.

The compounds of the present invention differ from those prior art compounds by their substitution on the 1-position of the piperidine moiety.

The present invention is concerned with 1,2-benzazoles having the formula



and the pharmaceutically acceptable acid addition salts or possible stereochemically isomeric forms thereof, wherein


R is hydrogen or C₁₋₆ alkyl;

R¹ and R² are each independently members selected from the group consisting of hydrogen, halo, hydroxy, C₁₋₆ alkyloxy and C₁₋₆ alkyl;

X is O or S;

Alk is C₁₋₄ alkanediyl; and

Q is a radical of formula




wherein Y¹ and Y² are each independently O or S;

R³ is a member selected from the group consisting of hydrogen, halo, C₁₋₆ alkyl, C₁₋₆ alkyloxy, trifluoromethyl, nitro, cyano, hydroxy, (C₁₋₁₀ alkylcarbonyl)oxy, amino, mono- and di(C₁₋₆ alkyl)amino, (C₁₋₁₀ alkylcarbonyl)amino, phenylmethoxy and azido;

R⁴ is hydrogen or halo; or

a radical of formula



wherein R⁵ is hydrogen or C₁₋₆ alkyl;

Z is -S-, -CH₂- or -CR⁶=CR⁷-; said R⁶ and R⁷ being each independently hydrogen or C₁₋₆ alkyl; and

A is a bivalent radical -CH₂-CH₂-, -CH₂-CH₂-CH₂- or -CR⁸=CR⁹-, said R⁸ and R⁹ being each independently hydrogen, halo, amino or C₁₋₆ alkyl.

In the foregoing definitions the term halo is generic to fluoro, chloro, bromo and iodo; "C₁₋₆ alkyl" is meant to include straight and branched saturated hydrocarbon radicals, having from 1 to 6 carbon atoms, such as, for example, methyl, ethyl, 1-methylethyl, 1,1-dimethylethyl, propyl, butyl, pentyl, hexyl; "C₁₋₄ alkanediyl" is meant to include bivalent straight or branch chained alkanediyl radicals having from 1 to 4 carbon atoms, such as, for example, methylene, ethylene, propylene, butylene; and "C₁₋₁₀ alkyl" is meant to include C₁₋₆ alkyl radicals, as defined hereinabove, and the higher homologs thereof having from 7 to 10

carbon atoms, such as, for example, heptyl, nonyl.

Preferred compounds within the invention are those wherein Q is a radical of formula (a) wherein R³ is hydrogen, halo, C₁₋₆ alkyl, C₁₋₆ alkyloxy, trifluoromethyl, hydroxy, amino or azido and R⁴ is hydrogen; or Q is a radical of formula (b) wherein R⁵ is C₁₋₆ alkyl and A is a bivalent radical -CH₂-CH₂-, -CH₂-CH₂-CH₂- or -CR⁸=CR⁹- wherein R⁸ and R⁹ are each independently hydrogen or C₁₋₆ alkyl.


Particularly preferred compounds are those preferred compounds wherein R is hydrogen, R¹ is hydrogen or halo and R² is hydrogen, halo, hydroxy or C₁₋₆ alkyloxy.

More particularly preferred compounds are those particularly preferred compounds wherein Q is a radical of formula (a) wherein R³ is hydrogen, halo or methyl and Y¹ is O; or Q is a radical of formula (b) wherein -Z-A- is -S-CH₂-CH₂-, -S-(CH₂)₃-, -S-CR⁸=CR⁹- wherein R⁸ and R⁹ are each independently hydrogen or methyl, -CH=CH-CR⁸=CR⁹- wherein R⁸ and R⁹ are each independently hydrogen or methyl, or -CH₂-CH₂-CH₂-CH₂-.

Especially preferred compounds are those more particularly preferred compounds wherein R¹ is hydrogen, and R² is hydrogen, halo, hydroxy or methoxy.

The most preferred compounds are selected from the group consisting of 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one and 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one and the pharmaceutically acceptable acid addition salts thereof.



The compounds of formula (I) can generally be prepared by reacting an appropriate reactive ester of formula (II) with an appropriately substituted piperidine of formula (III). In the reactive ester (II) W represents a reactive ester residue such as, for example, halo, e.g., chloro, bromo or iodo, or a sulfonyloxy group, e.g. methylsulfonyloxy, (4-methylphenyl)sulfonyloxy.




The reaction of (II) with (III) can conveniently be conducted in an inert organic solvent such as, for example, an aromatic hydrocarbon, e.g., benzene, methylbenzene, dimethylbenzene; a lower alkanol, e.g., methanol, ethanol, 1-butanol and the like; a ketone, e.g., 2-propanone, 4-methyl-2-pentanone; an ether, e.g., 1,4-dioxane, 1,1'-oxybisethane, tetrahydrofuran; N,N-dimethylformamide (DMF); N,N-dimethylacetamide (DMA); nitrobenzene; 1-methyl-2-pyrrolidinone. The addition of an appropriate base such as, for example, an alkali or an earth alkaline metal carbonate, hydrogen carbonate, hydroxide, alkoxide or hydride, e.g., sodium carbonate, sodium hydrogen carbonate, potassium carbonate, sodium hydroxide, sodium methoxide, sodium hydride, or an organic base such as, for example, a tertiary amine, e.g., N,N-diethylethanamine, N-(1-methylethyl)-2-propanamine, 4-ethylmorpholine may be utilized to pick up the acid which is liberated during the course of the reaction. In some circumstances the addition of a iodide salt, preferably an alkali metal iodide, is appropriate. Somewhat elevated temperatures may enhance the rate of the reaction.

The compounds of formula (I) may also be prepared following art-known procedures for preparing compounds containing radicals of formula Q within their structure.


For example, the compounds of formula (I) wherein Q is a radical of formula (a), said compounds being represented by the formula (I-a), can be prepared by cyclizing an appropriate 2-amino-benzamide or 2-aminobenzenethioamide of formula (IV-a) with urea or thiourea.



The compounds of formula (I-a) can also be prepared by cyclizing an appropriate intermediate of formula (IV-b) with an amine of formula (V)




or by cyclizing an isocyanate or isothiocyanate of formula (IV-c) with a primary amine of formula (V).



The said cyclization-reactions are conveniently conducted by stirring and, if desired, heating the reactants together, optionally in a suitable reaction-inert solvent having a relatively high boiling point such as aliphatic and aromatic hydrocarbons, e.g. petroleum ether, dimethylbenzene.

In the foregoing reaction schemes R^{10} and R^{10-a} each independently represent an appropriate leaving group such as, for example, C_1 - C_6 alkyloxy, amino, and mono- and di(C_1 - C_6 alkyl)amino.


The compounds of formula (I) wherein Q is a radical of formula (b), said compounds being represented by the formula (I-b), can be prepared following art-known cyclizing procedures for preparing pyrimidin-4-ones such as, for example, by reacting an amine of formula (VI) with a cyclizing agent of formula (VII) or by cyclizing a reagent of formula (VIII) with an amine of formula (IX).




The said cyclization reactions may generally be carried out by stirring the reactants together, if desired, in the presence of a suitable reaction-inert solvent such as, for example, an aliphatic-, alicyclic- or aromatic hydrocarbon, e.g., hexane, cyclohexane, benzene; pyridine; *N,N*-dimethylformamide. Elevated temperatures may be appropriate to enhance the reaction-rate. In some cases it may be preferable to carry out the reaction at the reflux temperature of the reaction mixture.

In the foregoing reaction schemes L and L¹ each independently represent an appropriate leaving group such as, for example, (C₁₋₆ alkyl)oxy, hydroxy, halo, amino, mono- and di(C₁₋₆ alkyl)amino.

Following the same cyclization procedure the compounds of formula (I-b) can also be prepared by cyclizing an intermediate of formula (IX) with a reagent of formula (X).




The compounds of formula (I-b) wherein Z is S, said compounds being represented by the formula (I-b-1), can also be prepared by cyclizing a 2-mercaptopyrimidinone of formula (XI) with a reagent of formula (XII).




In (XII) W' has the same meaning as previously described for W.

The compounds of formula (I-b-1) wherein A is



said compounds being represented by the formula (I-b-1-a), can also be prepared by cyclizing a 2-mercaptopyrimidinone of formula (XI) with a reagent of formula (XIII).



The cyclization reactions for preparing the compounds of formulae (I-b-1) and (I-b-1-a) may generally be carried out by stirring the reactants together, if desired, in the presence of a suitable reaction-inert solvent such as, for example, an aliphatic-, alicyclic- or aromatic hydrocarbon, e.g., hexane, cyclohexane, benzene; pyridine; *N,N*-dimethylformamide. Elevated temperatures may be appropriate to enhance the reaction-rate. In some cases it may be preferable to carry out the reaction at the reflux temperature of the reaction mixture.

The compounds of formula (I) may also be converted into each other following art-known functional group transformation procedures.

For example, the compounds of formula (I-a) wherein R³ is amino, may be derived from the corresponding nitro-substituted quinazolines following art-known nitro-to-amine reduction procedures. A suitable nitro-to-amine reducing procedure is, for example, catalytic hydrogenation in a relatively polar solvent such as, for example, an alcohol, e.g. methanol or ethanol, in the presence of an appropriate catalyst, e.g. platinum-on-charcoal. In some cases it may be useful to add an appropriate catalyst poison, e.g. thiophene.


The compounds of formula (I-a) wherein R³ is phenylmethoxy may be converted into compounds of formula (I-a) wherein R³ is hydroxy following art-known catalytic hydrogenolysis procedures; the compounds of formula (I-a) wherein R³ is amino or hydroxy may be converted into compounds of formula (I-a) wherein R³ is (C₁₋₁₀ alkylcarbonyl)amino or (C₁₋₁₀ alkylcarbonyl)oxy respectively by reacting the former compounds with a suitable acylating agent, e.g. an acylhalide or an acid anhydride; the compounds of formula (I-a) wherein R³ is an amino-group may be converted into compounds of formula (I-a) wherein R³ is an azido-group by converting the amino-group into a diazonium group with nitrous acid or an appropriate alkali

metal or earth alkaline metal thereof and subsequently converting the said diazonium group into an azide group with sodium azide or any other suitable alkali metal or earth alkaline metal azide.


The compounds of formula (I) have basic properties and, consequently, they may be converted to their therapeutically active non-toxic acid addition salt forms by treatment with appropriate acids, such as, for example, inorganic acids, such as hydrohalic acid, e.g. hydrochloric, hydrobromic and the like, and sulfuric acid, nitric acid, phosphoric acid and the like; or organic acids, such as, for example, acetic, propanoic, hydroxyacetic, 2-hydroxypropanoic, 2-oxopropanoic, ethanedioic, propanedioic, butanedioic, (Z)-2-butenedioic, (E)-2-butenedioic, 2-hydroxybutanedioic, 2,3-dihydroxybutanedioic, 2-hydroxy-1,2,3-propanetricarboxylic, methanesulfonic, ethanesulfonic, benzenesulfonic, 4-methylbenzenesulfonic, cyclohexanesulfamic, 2-hydroxybenzoic, 4-amino-2-hydroxybenzoic. Conversely the salt form can be converted by treatment with alkali into the free base form.

A number of intermediates and starting materials in the foregoing preparations are known compounds which may be prepared according to art-known methodologies of preparing said or similar compounds. For example, the intermediates of formula (II) and their preparations are described in U.S. Patent Nos. 4,335,127; 4,342,870; 4,443,451; and 4,485,107. Other intermediates may be prepared according to art-known methodologies of preparing similar compounds and for some of them preparative methods are presented hereinafter.


The intermediates of formula (III) may generally be derived from a benzoylpiperidine of formula




wherein halo is preferably fluoro, following art-known procedures, e.g. by reacting the benzoylpiperidine (XIV) with hydroxylamine and cyclizing the thus obtained oxime



following art-known procedures, thus obtaining the intermediate of formula (III) wherein X is O, said intermediates being represented by the formula



The intermediates of formula (III) wherein X is S, said intermediates being represented by the formula



may be prepared following a procedure analogous to the procedure described in U.S. Patent No. 4,458,076.

The compounds of formula (I) and the pharmaceutical acceptable acid addition salts thereof are potent antagonists of a series of neurotransmitters and as a result they have useful pharmacological properties. For example, the compounds of formula (I) and their pharmaceutically acceptable acid addition salts possess strong psychotic activity and antiserotonine activity.

Due to their pharmacological activities the compounds of formula (I) and their pharmaceutically acceptable acid addition salts can be used in the treatment of psychotic diseases and in the treatment of a variety of complaints in which serotonin release is of predominant importance such as, for example, in the blocking of serotonin-induced contractions of bronchial tissues and of blood vessels, arteries as well as veins. The subject compounds have also useful properties as sedating-, anxiolytic-, anti-aggressive-, anti-stress-, muscular protectant- and cardiovascular protectant agents and, consequently, they are useful to protect warm-blooded animals, for example, in stress situations, e.g., during transport periods. Additionally, the subject compounds are useful as protectors of endotoxine shocks and as antidiarrhoeals.

In view of their useful pharmacological properties, the subject compounds may be formulated into various pharmaceutical forms for administration purposes. To prepare the pharmaceutical compositions of this invention, an effective amount of the particular compound, in base or acid-addition salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration. These pharmaceutical compositions are desirably in unitary dosage form suitable, preferably, for administration orally, rectally, percutaneously, or by parenteral injection. For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols in the case of oral liquid preparations such as suspensions, syrups, elixirs and solutions; or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents in the case of powders, pills, capsules and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. For parenteral compositions, the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included. Injectable solutions, for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents may be employed. In the compositions suitable for percutaneous administration, the carrier optionally comprises a penetration enhancing agent and/or a suitable wettable agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not introduce a significant deleterious effect on the skin. Said additives may facilitate the administration to the skin and/or may be helpful for preparing the desired compositions. These compositions may be administered in various ways, e.g., as a transdermal patch, as a spot-on, as an ointment. Acid addition salts of (I) due to their increased water solubility over the corresponding base form, are obviously more suitable in the preparation of aqueous compositions.

It is especially advantageous to formulate the aforementioned pharmaceutical compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used in the specification and claims herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such dosage unit forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, injectable solutions or suspensions, teaspoonfuls, tablespoon-fuls, and segregated multiples thereof.

In the following examples, unless otherwise stated, all parts are by weight and all temperatures are in the centigrade scale.

EXPERIMENTAL PART

A) Preparation of the intermediates

Example 1

To a stirred mixture of 65 parts of 1,3-difluorobenzene, 130 parts of aluminium chloride and 195 parts of dichloromethane was added dropwise a solution of 95 parts of 1-acetyl-4-piperidine-carbonyl chloride in 65 parts of dichloromethane while cooling. Upon completion, stirring was continued for 3 hours at room temperature. The reaction mixture was poured into a mixture of crushed ice and hydrochloric acid. The product was extracted with dichloromethane. The organic layer was dried, filtered and evaporated, yielding

48 parts (36%) of 1-acetyl-4-(2,4-difluorobenzoyl)piperidine as a residue (intermediate 1).

A mixture of 48 parts of 1-acetyl-4-(2,4-difluorobenzoyl)piperidine and 180 parts of a hydrochloric acid solution 6N was stirred and refluxed for 5 hours. The reaction mixture was evaporated and the residue was stirred in 2-propanol. The product was filtered off and dried, yielding 39 parts (83%) of (2,4-difluorophenyl)-(4-piperidinyl)methanone hydrochloride (intermediate 2).

A mixture of 12 parts of (2,4-difluorophenyl)(4-piperidinyl)methanone hydrochloride, 12 parts of hydroxylamine hydrochloride and 120 parts of ethanol was stirred at room temperature and 10.5 parts of N,N-diethylethanamine were added. The whole was stirred and refluxed for 3 hours. After cooling, the precipitated product was filtered off and dried, yielding 11 parts (100%) of (2,4-difluorophenyl)(4-piperidinyl)methanone, oxime (intermediate 3).

A mixture of 11 parts of (2,4-difluorophenyl)(4-piperidinyl)methanone, oxime, 25 parts of potassium hydroxide and 25 parts of water was stirred and refluxed for 2 hours. The reaction mixture was cooled and extracted with methylbenzene. The extract was dried, filtered and evaporated. The residue was crystallized from petroleumether, yielding 6.8 parts of 6-fluoro-3-(4-piperidinyl)-1,2-benzisoxazole (intermediate 4).

Example 2

A mixture of 50 parts of 2-thiazolamine, 76 parts of 3-acetyl-4,5-dihydro-2(3H)-furanone, 1.2 parts of concentrate hydrochloric acid and 270 parts of methylbenzene was stirred and refluxed for 2 hours using a water-separator. The reaction mixture was cooled and 340 parts of phosphoryl chloride were added at a temperature between 20 and 30 °C. The whole was heated slowly to 100-110 °C and stirring was continued for 2 hours at this temperature. The reaction mixture was evaporated and the residue was poured into a mixture of crushed ice and ammonium hydroxide. The product was extracted with trichloromethane. The extract was dried, filtered and evaporated. The residue was purified by column chromatography over silica gel using a mixture of trichloromethane and methanol (95:5 by volume) as eluent. The pure fractions were collected and the eluent was evaporated. The residue was crystallized from a mixture of 2-propanol and 1,1'-oxybisethane, yielding 36 parts of 6-(2-chloroethyl)-7-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one (intermediate 5).

Example 3

A mixture of 30 parts of 4-hydroxy-2-mercapto-6-methyl-5-pyrimidineethanol, 25 parts of potassium carbonate, 270 parts of N,N-dimethylacetamide and 75 parts of water was stirred at room temperature and 36 parts of 1,3-dibromopropane were added at once: temperature rose to 50 °C. The whole was stirred overnight at room temperature. The reaction mixture was evaporated and water was added to the residue. The solid product was washed with water and dried in vacuo at 100 °C, yielding 21 parts (58%) of 3,4-dihydro-7-(2-hydroxyethyl)-8-methyl-2H,6H-pyrimido-[2,1-b][1,3]thiazin-6-one; mp. 155 °C (intermediate 6).

Following the same procedure and using equivalent amounts of the appropriate starting materials, there was also prepared:

2,3-dihydro-6-(2-hydroxyethyl)-7-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one; mp. 148.7 °C (intermediate 7).

Example 4

A mixture of 20 parts of 3,4-dihydro-7-(2-hydroxyethyl)-8-methyl-2H,6H-pyrimido[2,1-b][1,3]thiazin-6-one, 50 parts of acetic acid and 180 parts of a hydrobromic acid solution 67% in acetic acid was stirred and heated to reflux. Stirring was continued overnight at reflux temperature. The reaction mixture was evaporated and the solid residue was triturated in 2-propanone. The product was filtered off and dried, yielding 24 parts (100%) of 7-(2-bromoethyl)-3,4-dihydro-8-methyl-2H,6H-pyrimido[2,1-b][1,3]thiazin-6-one; monohydrobromide; mp. 215 °C (intermediate 8).

Following the same procedure and using equivalent amounts of the appropriate starting materials, there was also prepared:

6-(2-bromoethyl)-2,3-dihydro-7-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one monohydrochloride; mp. 237.2 °C (intermediate 9).

B) Preparation of the final compounds

Example 5

A mixture of 5.3 parts of 3-(2-chloroethyl)-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one monohydrochloride, 4.4 parts of 6-fluoro-3-(4-piperidinyl)-1,2-benzisoxazole, 8 parts of sodium carbonate, 0.1 parts of potassium iodide and 90 parts of N,N-dimethylformamide was stirred overnight at 85–90 °C. After cooling, the reaction mixture was poured into water. The product was filtered off and crystallized from a mixture of N,N-dimethylformamide and 2-propanol. The product was filtered off and dried, yielding 3.8 parts (46%) of 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one; mp. 170.0 °C (compound 1).

Following the same procedure and using equivalent amounts of the appropriate starting materials, there were also prepared:

6-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-7-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one; mp. 165.1 °C (compound 2);

3-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one; mp. 177.9 °C (compound 3);

3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,7-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; mp. 186.9 °C (compound 4);

3-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one; mp. 183.1 °C (compound 5);

3-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperidinyl]ethyl]-2,4(1H,3H)-quinazolinedione monohydrochloride; mp. >300 °C (dec.) (compound 6);

3-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one; mp. 145.7 °C (compound 7);

3-[2-[4-(6-hydroxy-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one; mp. 213.1 °C (compound 8).

In the similar manner are prepared

3-[2-[4-(5-methoxy-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one (compound 9);

3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one (compound 10).

Example 6

A mixture of 3.3 parts of 3-(2-chloroethyl)-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one, 3.3 parts of 6-fluoro-3-(4-piperidinyl)-1,2-benzisoxazole, 8 parts of sodium carbonate, 1 part of potassium iodide and 120 parts of 4-methyl-2-pentanone was stirred and refluxed for 3 hours. The reaction mixture was cooled, water was added and the layers were separated. The organic phase was dried, filtered and evaporated. The residue was purified by column chromatography over silica gel using a mixture of trichloromethane and methanol (95:5 by volume) as eluent. The pure fractions were collected and the eluent was evaporated. The residue was crystallized from 4-methyl-2-pentanone, yielding 1.2 parts (19%) of 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one; mp. 170.4 °C (compound 11).

Example 7

A mixture of 6.75 parts of 3-(2-chloroethyl)-2,4(1H,3H)-quinazolinedione, 6.6 parts of 6-fluoro-3-(4-piperidinyl)-1,2-benzisoxazole, 10 parts of sodium hydrogen carbonate, 0.1 parts of potassium iodide and 90 parts of N,N-dimethylformamide was stirred and heated overnight at 100–110 °C. After cooling, the reaction mixture was poured into water. After stirring, the product was filtered off and crystallized from N,N-dimethylformamide, yielding 4.8 parts (39%) of 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,4(1H,3H)-quinazolinedione; mp. 253.4 °C (compound 12).

Example 8

A mixture of 7.4 parts of 6-(2-bromoethyl)-3,7-dimethyl-5H-thiazolo[3,2-a]pyrimidin-5-one monohydrobromide, 4.4 parts of 6-fluoro-3-(4-piperidinyl)-1,2-benzisoxazole, 10 parts of sodium carbonate and 90 parts of N,N-dimethylformamide was stirred overnight at 80–85 °C. After cooling, the reaction mixture was poured into water. The product was filtered off and purified by column chromatography over silica gel using a mixture of trichloromethane and methanol (95:5 by volume) as eluent. The pure fractions were collected and the eluent was evaporated. 2-Propanol was added to the residue. The product was filtered off

and dried, yielding 5.3 parts (62%) of 6-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-3,7-dimethyl-5H-thiazolo[3,2-a]pyrimidin-5-one; mp. 231.0 °C (compound 13).

In a similar manner there were also prepared:

6-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,3-dihydro-7-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one; mp. 135.0 °C (compound 14);

7-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-3,4-dihydro-8-methyl-2H,6H-pyrimido[2,1-b][1,3]-thiazin-6-one;

mp. 169.3 °C (compound 15);

6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,3-dihydro-7-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one;

mp. 154.5 °C (compound 16).

3-[2-[4-(6-fluoro-1,2-benzisothiazol-3-yl)-1-piperidinyl]ethyl]-6,7,8, 9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one (compound 17);

3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,3-dihydro-2-thioxo-4(1H)-quinazolinone (compound 18).

C) Pharmacological examples

The activity of the subject compounds as psychotic agents is evidenced by the experimental data obtained in at least one of two different test procedures, viz., the combined apomorphine-, tryptamine- and norepinephrine tests in rats and the apomorphine test in dogs. The tests are carried out following the procedures described hereafter and the experimental data are summarized in table 1.

Example 9

The combined apomorphine (APO)-, tryptamine (TRY)- and norepinephrine (NOR) test in rats.

The experimental animals used in this test were adult male Wistar rats (weight 240 ± 10g). After an overnight fast, the animals were treated subcutaneously (1ml/100g) with an aqueous solution of the compound under investigation (time = zero) and put in isolated observation cages. Thirty minutes thereafter (time = 30 minutes) 1.25 mg/kg of apomorphine hydrochloride (APO) was injected intravenously and the rats were observed over a 1 hour period for the presence or absence of the following apomorphine-induced phenomena: agitation and stereotypic chewing. At the end of this 1 hour period (time = 90 minutes) the same animals were injected intravenously with 40 mg/kg of tryptamine (TRY) and the presence of the typical tryptamine-induced bilateral tonic seizures was noted. Two hours after pretreatment (time = 120 minutes) finally, the same animals were challenged with 1.25 mg/kg intravenously of norepinephrine (NOR) and possible mortality was looked for up to 60 minutes later.

The table 1 gives the ED₅₀-values of a number of the compounds under consideration. As used herein, the ED₅₀-value represents the dose which protects 50% of the animals from apomorphine-, tryptamine- or norepinephrine-induced phenomena.

The apomorphine test in dogs (APO-dog).

The method used is described by P.A.J. Janssen and C.J.E. Niemegeers in *Arzneim.-Forsch. (Drug Res.)*, 9, 765-767 (1959). The compounds listed in table 1 were administered subcutaneously to beagle dogs at different doses and the animals were challenged 1 hour thereafter with a standard dose of 0.31 mg/kg (subcutaneous) of apomorphine.

The table 1 gives the ED₅₀-values of a number of the compounds under consideration. As used herein, the ED₅₀ value represents the dose which protects 50% of the animals from emesis.

The compounds listed in table 1 are not given for the purpose of limiting the invention thereto but only to exemplify the useful pharmacological activities of all the compounds within the scope of formula (I).

Table i

Compound No.	ED ₅₀ (APO)-rat in mg/kg s.c.	ED ₅₀ (TRY)-rat in mg/kg s.c.	ED ₅₀ (NOR)-rat in mg/kg s.c.	ED ₅₀ (APO)-dog in mg/kg s.c. duration
1	0.08	0.08	0.16	1h. 0.008 2h. 0.005 4h. 0.015 8h. 0.018 16h. 0.02
2	0.02	0.005	0.31	1h. 0.004 4h. 0.008 16h. 0.16
11	0.02	0.01	0.16	1h. 0.015 4h. 0.03
13	0.02	0.02	0.08	1h. 0.015 4h. 0.06
14	0.02	0.005	0.31	1h. 0.004 4h. 0.004
15	0.08	0.01	0.31	1h. 0.015 4h. 0.06

D) Composition Examples

The following formulations exemplify typical pharmaceutical compositions in dosage unit form suitable for systemic administration to animal and human subjects in accordance with the instant invention.

"Active ingredient" (A.I.) as used throughout these examples relates to a compound of formula (I) or a pharmaceutically acceptable acid addition salt thereof.

Example 10 : ORAL DROPS

500 Grams of the A.I. was dissolved in 0.5 liters of 2-hydroxypropanoic acid and 1.5 liters of the polyethylene glycol at 60~80°C. After cooling to 30~40°C there were added 35 liters of polyethylene glycol and the mixture was stirred well. Then there was added a solution of 1750 grams of sodium saccharin in 2.5 liters of purified water and while stirring there were added 2.5 liters of cocoa flavor and

polyethylene glycol q.s. to a volume of 50 liters, providing an oral drop solution comprising 10 milligrams of the A.I. per milliliter. The resulting solution was filled into suitable containers.

Example 11 : ORAL SOLUTION

5

9 Grams of methyl 4-hydroxybenzoate and 1 gram of propyl 4-hydroxybenzoate were dissolved in 4 liters of boiling purified water. In 3 liters of this solution were dissolved first 10 grams of 2,3-dihydroxybutanedioic acid and thereafter 20 grams of the A.I. The latter solution was combined with the remaining part of the former solution and 12 liters 1,2,3-propanetriol and 3 liters of sorbitol 70% solution were added thereto. 40 Grams of sodium saccharin were dissolved in 0.5 liters of water and 2 milliliters of raspberry and 2 milliliters of gooseberry essence were added. The latter solution was combined with the former, water was added q.s. to a volume of 20 liters providing an oral solution comprising 20 milligrams of the active ingredient per teaspoonful (5 milliliters). The resulting solution was filled in suitable containers.

Example 12 : CAPSULES

15

20 Grams of the A.I., 6 grams sodium lauryl sulfate, 56 grams starch, 56 grams lactose, 0.8 grams colloidal silicon dioxide, and 1.2 grams magnesium stearate were vigorously stirred together. The resulting mixture was subsequently filled into 1000 suitable hardened gelating capsules, comprising each 20 milligrams of the active ingredient.

Example 13 : FILM-COATED TABLETS

Preparation of tablet core

25

A mixture of 100 grams of the A.I., 570 grams lactose and 200 grams starch was mixed well and thereafter humidified with a solution of 5 grams sodium dodecyl sulfate and 10 grams polyvinylpyrrolidone (Kollidon-K 90®) in about 200 milliliters of water. The wet powder mixture was sieved, dried and sieved again. Then there was added 100 grams microcrystalline cellulose (Avicel®) and 15 grams hydrogenated vegetable oil (Sterotex ®). The whole was mixed well and compressed into tablets, giving 10.000 tablets, each containing 10 milligrams of the active ingredient.

Coating

35

To a solution of 10 grams methyl cellulose (Methocel 60 HG®) in 75 milliliters of denaturated ethanol there was added a solution of 5 grams of ethyl cellulose (Ethocel 22 cps ®) in 150 milliliters of dichloromethane. Then there were added 75 milliliters of dichloromethane and 2.5 milliliters 1,2,3-propanetriol. 10 Grams of polyethylene glycol was molten and dissolved in 75 milliliters of dichloromethane. The latter solution was added to the former and then there were added 2.5 grams of magnesium octadecanoate, 5 grams of polyvinylpyrrolidone and 30 milliliters of concentrated colour suspension (Opaspray K-1-2109®) and the whole was homogenated. The tablet cores were coated with the thus obtained mixture in a coating apparatus.

Example 14 : INJECTABLE SOLUTION

45

1.8 Grams methyl 4-hydroxybenzoate and 0.2 grams propyl 4-hydroxybenzoate were dissolved in about 0.5 liters of boiling water for injection. After cooling to about 50° C there were added while stirring 4 grams lactic acid, 0.05 grams propylene glycol and 4 grams of the A.I.. The solution was cooled to room temperature and supplemented with water for injection q.s. ad 1 liter volume, giving a solution of 4 milligrams A.I. per milliliters. The solution was sterilized by filtration (U.S.P. XVII p. 811) and filled in sterile containers.

Example 15 : SUPPOSITORIES


55

3 Grams A.I. was dissolved in a solution of 3 grams 2,3-dihydroxybutanedioic acid in 25 milliliters polyethylene glycol 400. 12 Grams surfactant (SPAN®) and triglycerides (Witepsol 555 ®) q.s. ad 300 grams were molten together. The latter mixture was mixed well with the former solution. The thus obtained mixture was poured into moulds at a temperature of 37-38° C to form 100 suppositories each containing 30

milligrams of the active ingredient.

Claims

1. A chemical compound having the formula



or a pharmaceutically acceptable acid addition salt thereof,
wherein


R is hydrogen or C₁₋₆ alkyl;

R¹ and R² are each independently members selected from the group consisting of hydrogen, halo, hydroxy, C₁₋₆ alkyloxy and C₁₋₆ alkyl;

X is O or S;

Alk is C₁₋₄ alkanediyl; and


Q is a radical of formula



wherein Y¹ and Y² are each independently O or S;

R³ is a member selected from the group consisting of hydrogen, halo, C₁₋₆ alkyl, C₁₋₆ alkyloxy, trifluoromethyl, nitro, cyano, hydroxy, (C₁₋₁₀ alkylcarbonyl)oxy, amino, mono- and di(C₁₋₆ alkyl)amino, (C₁₋₁₀ alkylcarbonyl)amino, phenylmethoxy and azido;

R⁴ is hydrogen or halo; or
a radical of formula



wherein R⁵ is hydrogen or C₁₋₆ alkyl;

Z is -S-, -CH₂- or -CR⁶=CR⁷-; said R⁶ and R⁷ being each independently hydrogen or C₁₋₆ alkyl;
and


A is a bivalent radical -CH₂-CH₂-, -CH₂-CH₂-CH₂- or -CR⁸=CR⁹-, said R⁸ and R⁹ being each independently hydrogen, halo, amino or C₁₋₆ alkyl.

2. A chemical compound according to claim 1, wherein Q is a radical of formula (a) wherein R³ is hydrogen, halo, C₁₋₆ alkyl, C₁₋₆ alkyloxy, trifluoromethyl, hydroxy, amino or azido and R⁴ is hydrogen; or Q is a radical of formula (b) wherein R⁵ is C₁₋₆ alkyl and A is a bivalent radical -CH₂-CH₂-, -CH₂-CH₂-CH₂- or -CR⁸=CR⁹- wherein R⁸ and R⁹ are each independently hydrogen or C₁₋₆ alkyl.
3. A chemical compound according to claim 2, wherein R is hydrogen, R¹ is hydrogen or halo and R² is hydrogen, halo, hydroxy or C₁₋₆ alkyloxy.


4. A chemical compound according to claim 3, wherein Q is a radical of formula (a) wherein R³ is hydrogen, halo or methyl and Y¹ is O; or Q is a radical of formula (b) wherein -Z-A- is -S-CH₂-CH₂-, -S-(CH₂)₃-, -S-CR⁸=CR⁹- wherein R⁸ and R⁹ are each independently hydrogen or methyl, -CH=CH-CR⁸=CR⁹-wherein R⁸ and R⁹ are each independently hydrogen or methyl, or -CH₂-CH₂-CH₂-CH₂-.
5. A chemical compound according to claim 4, wherein R¹ is hydrogen, and R² is hydrogen, halo, hydroxy or methoxy.
6. A chemical compound according to claim 1 wherein the compound is 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one or 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one.
7. A pharmaceutical composition comprising a suitable pharmaceutical carrier and as an active ingredient a therapeutically active amount of a compound as claimed in any one of claims 1 to 6.
8. A pharmaceutical composition for treating psychotic diseases comprising a suitable pharmaceutical carrier and as an active ingredient an amount effective in treating psychotic diseases of a compound as claimed in any one of claims 1 to 6.
9. A method of preparing a pharmaceutical composition characterized in that a therapeutically effective amount of a compound as claimed in any one of claims 1 to 6 is intimately mixed with suitable pharmaceutical carriers.
10. A compound as claimed in any one of claims 1 to 6 for use as a medicine.
11. A compound as claimed in any one of claims 1 to 6 for use as a medicine for treating psychotic diseases.
12. A process for preparing a chemical compound as claimed in any of claims 1 to 6, characterized by
a) reacting a derivative ester of formula




wherein W represents a reactive ester residue with a piperidine of formula




- in a reaction-inert solvent;
b) cyclizing an intermediate of formula




with urea or thiourea, optionally in a reaction-inert solvent, thus preparing a compound of formula




10 c) cyclizing an intermediate of formula



20 wherein R^{10} and R^{10-a} each independently represent a leaving group such as, C_{1-6} alkyloxy, amino and mono- and di(C_{1-6} alkyl)amino, with an amine of formula




30 optionally in a reaction-inert solvent, thus preparing a compound of formula (I-a);
d) cyclizing an isocyanate or isothiocyanate of formula




40 with an amine of formula (V), optionally in a reaction-inert solvent, thus preparing a compound of formula (I-a);


45 e) reacting an amine of formula




55 with a α -carbonylcarboxylic acid derivative of formula




10 wherein L represents a leaving group such as, C₁₋₆ alkyloxy, hydroxy, halo, amino, mono- and di-(C₁₋₆ alkyl)amino, thus preparing a compound of formula



20 f) cyclizing a reagent of formula




with an β -aminocarboxylic acid derivative of formula




40 said L and L¹ each independently representing a leaving group such as, C₁₋₆ alkyloxy, hydroxy, halo, amino, mono- and di-(C₁₋₆ alkyl)amino, thus preparing a compound of formula (I-b);

g) cyclizing a nitrile of formula



50 with an β -aminocarboxylic acid derivative of formula (IX) said L representing a leaving group such as, C₁₋₆ alkyloxy, hydroxy, halo, amino, mono- and di-(C₁₋₆ alkyl)amino, thus preparing a compound of formula (I-b);


h) cyclizing a 2-mercaptopyrimidinone of formula



10 with a reagent of formula




20 thus preparing a compound of formula (I-b) wherein Z is S, said compounds being represented by the formula




or


30 i) cyclizing a 2-mercaptopyrimidinone of formula (XI) with a reagent of formula



thus preparing a compound of formula (I-b) wherein Z is S and A is



said compounds being represented by the formula



55 j) converting the compounds of formula (I-a), as defined hereinabove under b), wherein R³ is nitro to the corresponding amino compounds by an art-known nitro to amino reduction procedure;

k) converting the compounds of formula (I-a) as defined hereinabove under b), wherein R³ is phenylmethoxy into compounds of formula (I-a) wherein R³ is hydroxy by art-known catalytic hydrogenolysis procedures;

l) converting the compounds of formula (I-a), as defined hereinabove under b), wherein R³ is amino


or hydroxy into compounds of formula (I-a) wherein R^3 is $(C_1-6\text{alkylcarbonyl})\text{oxy}$ by reacting the starting compounds with an acylating agent;

m) converting the compounds of formula (I-a), as defined hereinabove under b), wherein R^3 is an amino group into compounds of formula (I-a) wherein R^3 is an azido group by converting the amino group into a diazonium group and subsequently converting the said diazonium group into an azide group;

or, optionally converting the compounds of formula (I) into each other following art-known group transformation procedures, and, if desired, converting the compounds of formula (I) into a therapeutically active non-toxic acid addition salt form by treatment with an appropriate acid or, conversely, converting the acid-addition salt into the free base form with alkali; and/or preparing stereochemically isomeric forms thereof.

Revendications

1. Un composé chimique ayant la formule



ou un sel par addition d'acide pharmaceutiquement acceptable de celui-ci, dans laquelle


R est l'hydrogène ou un alkyle en C_1-6 ;

R^1 et R^2 sont chacun des membres indépendants pris dans le groupe constitué par l'hydrogène, un groupement halo, hydroxy, alkyloxy en C_1-6 et alkyle en C_1-6 ;

X est O ou S;

Alk est un alcanediyle en C_1-4 ; et


Q est un radical de formule



dans laquelle Y^1 et Y^2 sont chacun indépendamment O ou S;

R^3 est un membre choisi dans le groupe consistant en l'hydrogène, un groupement halo, alkyloxy en C_1-6 , alkyle en C_1-6 , trifluorométhyle, nitro, cyano, hydroxy, (alkylcarbonyl en C_1-10)oxy, amino, mono- et di(alkyle en C_1-6)amino, (alkylcarbonyl en C_1-10)amino, phénylméthoxy et azido;

R^4 est un hydrogène ou un groupement halo; ou un radical de formule



dans laquelle R^5 est l'hydrogène ou un alkyle en C_1-6 ;

Z est -S-, -CH₂- ou -CR⁶ = CR⁷-; lesdits R^6 et R^7 étant chacun indépendamment de l'hydrogène ou un alkyle en C_1-6 ; et


A est un radical bivalent -CH₂-CH₂-, -CH₂-CH₂-CH₂- ou -CR⁸ = CR⁹-, lesdits R^8 et R^9 étant chacun

indépendamment l'hydrogène, un groupement halo, amino ou alkyle en C₁₋₆.


2. Un composé chimique selon la revendication 1, dans lequel Q est un radical de formule (a) dans laquelle R³ est un hydrogène, un groupement halo, alkyloxy en C₁₋₆, alkyle en C₁₋₆, trifluorométhyle, hydroxy, amino ou azido et R⁴ est l'hydrogène ; ou Q est un radical de formule (b) dans laquelle R⁵ est un alkyle en C₁₋₆ et A est un radical bivalent -CH₂-CH₂-, -CH₂-CH₂-CH₂- ou -CR⁸=CR⁹-, avec R⁸ et R⁹ qui sont chacun indépendamment l'hydrogène ou un alkyle en C₁₋₆.
3. Un composé chimique selon la revendication 2, dans lequel R est l'hydrogène, R¹ est l'hydrogène ou un groupement halo et R² est l'hydrogène, un groupement halo, hydroxy ou alkyloxy en C₁₋₆.
4. Un composé chimique selon la revendication 3, dans lequel Q est un radical de formule (a) dans laquelle R³ est l'hydrogène, un groupement halo ou méthyle et Y¹ est O ; ou Q est un radical de formule (b) dans laquelle -Z-A- est S-CH₂-CH₂-, -S-(CH₂)₃-, -S-CR⁸=CR⁹- avec R⁸ et R⁹ qui sont chacun indépendamment l'hydrogène ou un groupement méthyle, -CH=CH-CR⁸=CR⁹- avec R⁸ et R⁹ qui sont chacun indépendamment l'hydrogène ou un groupement méthyle, ou -CH₂-CH₂-CH₂-CH₂-.
5. Un composé chimique selon la revendication 4, dans lequel R¹ est l'hydrogène, et R² est l'hydrogène, un groupement halo, hydroxy ou méthoxy.
6. Un composé chimique selon la revendication 1, où le composé est la 3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yle)-1-pipéridinyle]éthyle}-6,7,8,9-tétrahydro-2-méthyle-4H-pyrido[1,2-a]pyrimidine-4-one ou la 3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yle)-1-pipéridinyle]éthyle}-2-méthyle-4H-pyrido[1,2-a]pyrimidine-4-one.
7. Une composition pharmaceutique comprenant un transporteur pharmaceutique convenable et en tant qu'ingrédient actif une quantité thérapeutiquement active d'un composé selon l'une quelconque des revendications 1 à 6.
8. Une composition pharmaceutique pour traiter les maladies psychotiques comprenant un transporteur pharmaceutique convenable et en tant qu'ingrédient actif une quantité active pour traiter les maladies psychotiques d'un composé selon l'une quelconque des revendications 1 à 6.
9. Une méthode pour préparer une composition pharmaceutique caractérisée en ce qu'une quantité thérapeutiquement active d'un composé selon l'une quelconque des revendications 1 à 6 est intimement mélangée avec des transporteurs pharmaceutiques convenables.
10. Un composé selon l'une quelconque des revendications 1 à 6 pour un usage en tant que médicament.
11. Un composé selon l'une quelconque des revendications 1 à 6 pour un usage en tant que médicament pour soigner les maladies psychotiques.
12. Un procédé pour préparer un composé chimique selon l'une quelconque des revendications 1 à 6, caractérisé par
 - a) mettre en réaction d'un dérivé d'ester de formule




dans laquelle W représente un résidu ester réactif avec une pipéridine de formule




- b) cycliser un intermédiaire de formule




10 avec de l'urée ou de la thiourée, facultativement dans un solvant inerte pour la réaction, préparant ainsi un composé de formule




20 c) cycliser un intermédiaire de formule



30 dans laquelle R^{10} et R^{10-a} représentent chacun indépendamment un groupe partant tel que, un alkyloxy en C_{1-6} , un amino, et un mono- et di(alkyle en C_{1-6})amino, avec une amine de formule




45 facultativement dans un solvant inerte pour la réaction, préparant ainsi un composé de formule (I-a) ;
d) cycliser un isocyanate ou un isothiocyanate de formule




55 avec une amine de formule (V), facultativement dans un solvant inerte pour la réaction, préparant ainsi un composé de formule (I-a) ;


e) mettre en réaction une amine de formule




avec un dérivé d'acide α -carboxylique de formule




dans laquelle L représente un groupe partant tel que, un groupement alkyloxy en C_{1-6} , hydroxy, halo, amino, mono- et di(alkyle en C_{1-6})amino, préparant ainsi un composé de formule



f) cycliser un réactif de formule




avec un dérivé d'acide β -aminocarboxylique de formule




lesdits L et L^1 représentant chacun indépendamment un groupe partant tel que, un groupement alkyloxy en C_{1-6} , hydroxy, halo, amino, mono- et di(alkyle en C_{1-6})amino, préparant ainsi un composé de formule (I-b) ;

g) cycliser un nitrile de formule




avec un dérivé d'acide β -aminocarboxylique de formule (IX) ledit L représentant un groupe partant tel que, un groupement alkyloxy en C_{1-6} , hydroxy, halo, amino, mono- et di(alkyle en C_{1-6})amino, préparant ainsi un composé de formule (I-b) ;


h) cycliser une 2-mercaptopyrimidone de formule



avec un réactif de formule




préparant ainsi un composé de formule (I-b) dans laquelle Z est S, lesdits composés étant représentés par la formule :




ou


i) cycliser une 2-mercaptopyrimidinone de formule (XI) avec un réactif de formule



préparant ainsi un composé de formule (I-b) dans laquelle Z est S et A est



lesdits composés étant représentés par la formule



j) convertir les composés de formule (I-a), ainsi qu'ils sont définis ci-dessus au b), dans laquelle R³ est un groupement nitro en les composés aminés correspondants par un procédé connu dans l'art de réduction de nitro en amine ;

k) convertir les composés de formule (I-a), ainsi qu'ils sont définis ci-dessus au b), dans laquelle R³ est un groupement phénylméthoxy en les composés de formule (I-a) dans laquelle R³ est un groupement hydroxy par des procédés connus dans l'art d'hydrogénolyse catalytique ;


l) convertir les composés de formule (I-a), ainsi qu'ils sont définis ci-dessus au b), dans laquelle R³ est un groupement amino ou hydroxy en les composés de formule (I-a) dans laquelle R³ est un groupement (alkylcarbonyl en C₁₋₆)oxy en faisant réagir les composés de départ avec un agent d'acylation ;

m) convertir les composés de formule (I-a), ainsi qu'ils sont définis ci-dessus au b), dans laquelle R³ est un groupement amino en les composés de formule (I-a) dans laquelle R³ est un groupement azohydrure en convertissant le groupement amino en un groupement diazonium et en convertissant subséquemment ledit groupement diazonium en un groupement azohydrure ;

ou, convertir facultativement les composés de formule (I) chacun l'un en l'autre en suivant des procédés connus de l'art de transformation de groupes, et, si désiré, convertir les composés de formule (I) en un sel d'addition d'acide non toxique thérapeutiquement actif par traitement avec un acide approprié ou, réciproquement, convertir le sel d'addition d'acide en sa forme de base libre avec de l'alcali ; et/ou préparer des formes isomères stéréochimiques de ceux-ci.


Patentansprüche

1. Chemische Verbindung mit der Formel




oder ein pharmazeutisch annehmbares Säureadditionssalz hiervon, worin

- R Wasserstoff oder C₁₋₆ Alkyl bedeutet;
 R¹ und R² jeweils unabhängig voneinander Glieder aus der aus Wasserstoff, Halogen, Hydroxy, C₁₋₆ Alkyloxy und C₁₋₆ Alkyl bestehenden Gruppe sind;
 X für O oder S steht;
 Alk für C₁₋₄ Alkandiyl steht; und
 Q einen Rest der Formel



worin

- Y¹ und Y² jeweils unabhängig voneinander für O oder S stehen;
 R³ für ein Glied steht, ausgewählt aus der aus Wasserstoff, Halogen, C₁₋₆ Alkyl, C₁₋₆ Alkyloxy, Trifluormethyl, Nitro, Cyano, Hydroxy, (C₁₋₁₀ Alkylcarbonyl)oxy, Amino, Mono- und Di(C₁₋₆ alkyl)amino, (C₁₋₁₀ Alkylcarbonyl)amino, Phénylmethoxy und Azido bestehenden Gruppe;
 R⁴ für Wasserstoff oder Halogen steht; oder
 einen Rest der Formel



(b)

5

bedeutet, worin

- 10 R^5 für Wasserstoff oder C_{1-6} Alkyl steht;
 Z die Bedeutung -S-, -CH₂- oder -CR⁶ = CR⁷- hat; wobei die Reste R^6 und R^7 jeweils unabhängig voneinander Wasserstoff oder C_{1-6} Alkyl bedeuten; und
 A einen zweiwertigen Rest -CH₂-CH₂-, -CH₂-CH₂-CH₂- oder -CR⁸ = CR⁹- darstellt, worin R^8 und R^9 jeweils unabhängig voneinander Wasserstoff, Halogen, Amino oder C_{1-6} Alkyl bedeuten.

- 15 2. Chemische Verbindung nach Anspruch 1, worin Q einen Rest der Formel (a) bedeutet, worin R^3 für Wasserstoff, Halogen, C_{1-6} Alkyl, C_{1-6} Alkyloxy, Trifluormethyl, Hydroxy, Amino oder Azido steht und R^4 Wasserstoff bedeutet; oder Q für einen Rest der Formel (b) steht, worin R^5 C_{1-6} Alkyl darstellt und A einen zweiwertigen Rest -CH₂-CH₂-, -CH₂-CH₂-CH₂- oder -CR⁸ = CR⁹- bedeutet, worin R^8 und R^9 jeweils unabhängig voneinander Wasserstoff oder C_{1-6} Alkyl bedeuten.

20

3. Chemische Verbindung nach Anspruch 2, worin R Wasserstoff darstellt, R^1 für Wasserstoff oder Halogen steht und R^2 Wasserstoff, Halogen, Hydroxy oder C_{1-6} Alkyloxy darstellt.

- 25 4. Chemische Verbindung nach Anspruch 3, worin Q einen Rest der Formel (a) bedeutet, worin R^3 für Wasserstoff, Halogen oder Methyl steht und Y^1 die Bedeutung O hat; oder Q für einen Rest der Formel (b) steht, worin -Z-A- für -S-CH₂-CH₂-, -S-(CH₂)₃-, -S-CR⁸ = CR⁹- steht, worin R^8 und R^9 jeweils unabhängig voneinander Wasserstoff oder Methyl bedeuten, für -CH=CH-CR⁸ = CR⁹-steht, worin R^8 und R^9 jeweils unabhängig voneinander Wasserstoff oder Methyl bedeuten, oder für -CH₂-CH₂-CH₂-CH₂- steht.

30

5. Chemische Verbindung nach Anspruch 4, worin R^1 Wasserstoff ist und R^2 für Wasserstoff, Halogen, Hydroxy oder Methoxy steht.

- 35 6. Chemische Verbindung nach Anspruch 1, worin die Verbindung 3-[2-[4-(6-Fluor 1,2-benzisoxazol-3-yl)-1-piperidinyl] ethyl] -6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-on oder 3-[2-[4-(6-Fluor 1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]2-methyl-4H-pyrido[1,2-a]pyrimidin-4-on ist.

- 40 7. Pharmazeutische Zusammensetzung, umfassend einen geeigneten pharmazeutischen Träger und als einen wirksamen Bestandteil eine therapeutisch wirksame Menge einer Verbindung nach einem der Ansprüche 1 bis 6.

8. Pharmazeutische Zusammensetzung zur Behandlung psychotischer Erkrankungen, umfassend einen geeigneten pharmazeutischen Träger und als einen wirksamen Bestandteil eine zur Behandlung psychotischer Erkrankungen wirksame Menge einer Verbindung nach einem der Ansprüche 1 bis 6.

45

9. Verfahren zur Herstellung einer pharmazeutischen Zusammensetzung, dadurch gekennzeichnet, daß eine therapeutisch wirksame Menge einer Verbindung nach einem der Ansprüche 1 bis 6 innig mit geeigneten pharmazeutischen Trägern vermischt wird.

- 50 10. Verbindung nach einem der Ansprüche 1 bis 6 zur Verwendung als eine Medizin.


11. Verbindung nach einem der Ansprüche 1 bis 6 zur Verwendung als Medizin zur Behandlung psychotischer Erkrankungen.

- 55 12. Verfahren zur Herstellung einer chemischen Verbindung nach einem der Ansprüche 1 bis 6, gekennzeichnet durch:

a) Umsetzen eines Esterderivats der Formel


Q-Alk-W (II),

worin W einen reaktionsfähigen Esterrest bedeutet, mit einem Piperidin der Formel




in einem reaktionsinerten Lösungsmittel;


b) Cyclisieren eines Zwischenproduktes der Formel




mit Harnstoff oder Thioharnstoff, gegebenenfalls in einem reaktionsinerten Lösungsmittel, zu einer Verbindung der Formel



c) Cyclisieren eines Zwischenproduktes der Formel




worin R^{10} und R^{10-a} jeweils unabhängig voneinander eine Leaving-Gruppe, wie C_1 - C_6 Alkyloxy, Amino und Mono- und Di(C_1 - C_6 alkyl)amino bedeuten, mit einem Amin der Formel




gegebenenfalls in einem reaktionsinerten Lösungsmittel, unter Ausbildung einer Verbindung der Formel (I-a);

d) Cyclisieren eines Isocyanats oder Isothiocyanats der Formel




mit einem Amin der Formel (V), gegebenenfalls in einem reaktionsinerten Lösungsmittel, unter Ausbildung einer Verbindung der Formel (I-a);


e) Umsetzen eines Amins der Formel



mit einem α -Carbonylcarbonsäurederivat der Formel




worin L eine Leaving-Gruppe, wie C₁-₆ Alkyloxy, Hydroxy, Halogen, Amino, Mono- und Di(C₁-₆ alkyl)-amino bedeutet, unter Ausbildung einer Verbindung der Formel



f) Cyclisieren eines Reagens der Formel



mit einem β -Aminocarbonsäurederivat der Formel




10 worin L und L¹ jeweils unabhängig voneinander eine Leaving-Gruppe, wie C₁-₆ Alkyloxy, Hydroxy, Halogen, Amino, Mono- und Di(C₁-₆ Alkyl)amino bedeuten, unter Ausbildung einer Verbindung der Formel (I-b);

g) Cyclisieren eines Nitrils der Formel



20 mit einem β-Aminocarbonsäurederivat der Formel (IX), worin L eine Leaving-Gruppe wie C₁-₆-Alkyloxy, Hydroxy, Halogen, Amino, Mono- und Di(C₁-₆ alkyl)amino bedeutet, unter Ausbildung einer Verbindung der Formel (I-b);


h) Cyclisieren eines 2-Mercaptopyrimidinons der Formel



30 mit einem Reagens der Formel




40 unter Ausbildung einer Verbindung der Formel (I-b), worin Z für S steht, welche Verbindungen durch die Formel




50 dargestellt werden; oder

i) Cyclisieren eines 2-Mercaptopyrimidinons der Formel (XI) mit einem Reagens der Formel




(XIII)

unter Ausbildung einer Verbindung der Formel (I-b), worin Z für S steht und A die Bedeutung



hat, welche Verbindungen durch die Formel



dargestellt werden;

j) Überführen der Verbindungen der Formel (I-a), wie vorstehend unter b) definiert, worin R³ für Nitro steht, in die entsprechenden Aminoverbindungen nach bekannten Nitro- zu Amino-Reduktionsverfahren;

k) Überführen der Verbindungen der Formel (I-a), wie vorstehend unter b) definiert, worin R³ für Phenylmethoxy steht, nach bekannten katalytischen Hydrogenolyseverfahren in Verbindungen der Formel (I-a), worin R³ für Hydroxy steht;

l) Überführen der Verbindungen der Formel (I-a), wie vorstehend unter b) definiert, worin R³ für Amino oder Hydroxy steht, durch Umsetzen der Ausgangsverbindungen mit einem Acylierungsmittel in Verbindungen der Formel (I-a), worin R³ für (C₁-₆ Alkylcarbonyl)oxy steht;

m) Überführen von Verbindungen der Formel (I-a), wie vorstehend unter b) definiert, worin R³ eine Aminogruppe bedeutet, in Verbindungen der Formel (I-a), worin R³ eine Azidogruppe darstellt, indem die Aminogruppe in eine Diazoniumgruppe umgewandelt wird und anschließend diese Diazoniumgruppe in eine Azidgruppe umgewandelt wird;

oder gewünschtenfalls Umwandeln der Verbindungen der Formel (I) ineinander nach bekannten Gruppentransformationsverfahren und gewünschtenfalls Überführen der Verbindungen der Formel (I) in eine therapeutisch wirksame nicht-toxische Säureadditionssalzform durch Behandeln mit einer entsprechenden Säure oder, umgekehrt, Umwandeln des Säureadditionssalzes mit Alkali in die freie Basenform; und/oder Herstellen stereochemisch isomerer Formen hiervon.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.